Memantine can protect against inflammation-based cognitive decline in geriatric depression

INTRODUCTION: Geriatric depression is frequently accompanied by cognitive complaints and inflammation that increase risk for treatment-resistant depression and dementia. Memantine, a neuroprotective drug, can improve depression, inflammation, and help prevent cognitive decline. In our six-month clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Dyk, Kathleen, Siddarth, Prabha, Rossetti, Maura, Ercoli, Linda M., Milillo, Michaela M., Lavretsky, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474499/
https://www.ncbi.nlm.nih.gov/pubmed/34589902
http://dx.doi.org/10.1016/j.bbih.2020.100167
_version_ 1784575237914886144
author Van Dyk, Kathleen
Siddarth, Prabha
Rossetti, Maura
Ercoli, Linda M.
Milillo, Michaela M.
Lavretsky, Helen
author_facet Van Dyk, Kathleen
Siddarth, Prabha
Rossetti, Maura
Ercoli, Linda M.
Milillo, Michaela M.
Lavretsky, Helen
author_sort Van Dyk, Kathleen
collection PubMed
description INTRODUCTION: Geriatric depression is frequently accompanied by cognitive complaints and inflammation that increase risk for treatment-resistant depression and dementia. Memantine, a neuroprotective drug, can improve depression, inflammation, and help prevent cognitive decline. In our six-month clinical trial, escitalopram/memantine (ESC/MEM) improved mood and cognition compared to escitalopram/placebo treatment (ESC/PBO; NCT01902004). In this report, we examined the impact of baseline inflammation on mood and cognitive outcomes. MATERIALS AND METHODS: We measured a panel of inflammatory cytokine markers using Human 38-plex magnetic cytokine/chemokine kits (EMD Millipore, HCYTMAG-60K-PX38) in 90 older adults 60 years and older with major depression enrolled in a 6-month double-blind placebo-controlled trial of escitalopram ​+ ​memantine (ESC/MEM) in depressed older adults with subjective memory complaints. Four cytokine factors were derived and linear models were estimated to examine the predictive ability of cytokine levels on treatment induced change in depression and cognition. RESULTS: Of the 90 randomized participants, 62 completed the 6-month follow up assessment. Both groups improved significantly on depression severity (HAM-D score), but not on cognitive outcomes at six months. Cytokine factor scores were not significantly different between ESC/MEM (n ​= ​45) and ESC/PBO (n ​= ​45) at baseline. Pro-inflammatory biomarkers at baseline predicted a decline in executive functioning in the ESC/PBO group but not in the ESC/MEM group, interaction F(1,52) ​= ​4.63, p ​= ​.04. DISCUSSION: In this exploratory analysis, the addition of memantine to escitalopram provided a protective effect on executive functioning in older depressed adults. Future studies are needed to replicate the association of cytokine markers to antidepressant and neuroprotective treatment-related change in cognition in geriatric depression.
format Online
Article
Text
id pubmed-8474499
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84744992021-09-28 Memantine can protect against inflammation-based cognitive decline in geriatric depression Van Dyk, Kathleen Siddarth, Prabha Rossetti, Maura Ercoli, Linda M. Milillo, Michaela M. Lavretsky, Helen Brain Behav Immun Health Full Length Article INTRODUCTION: Geriatric depression is frequently accompanied by cognitive complaints and inflammation that increase risk for treatment-resistant depression and dementia. Memantine, a neuroprotective drug, can improve depression, inflammation, and help prevent cognitive decline. In our six-month clinical trial, escitalopram/memantine (ESC/MEM) improved mood and cognition compared to escitalopram/placebo treatment (ESC/PBO; NCT01902004). In this report, we examined the impact of baseline inflammation on mood and cognitive outcomes. MATERIALS AND METHODS: We measured a panel of inflammatory cytokine markers using Human 38-plex magnetic cytokine/chemokine kits (EMD Millipore, HCYTMAG-60K-PX38) in 90 older adults 60 years and older with major depression enrolled in a 6-month double-blind placebo-controlled trial of escitalopram ​+ ​memantine (ESC/MEM) in depressed older adults with subjective memory complaints. Four cytokine factors were derived and linear models were estimated to examine the predictive ability of cytokine levels on treatment induced change in depression and cognition. RESULTS: Of the 90 randomized participants, 62 completed the 6-month follow up assessment. Both groups improved significantly on depression severity (HAM-D score), but not on cognitive outcomes at six months. Cytokine factor scores were not significantly different between ESC/MEM (n ​= ​45) and ESC/PBO (n ​= ​45) at baseline. Pro-inflammatory biomarkers at baseline predicted a decline in executive functioning in the ESC/PBO group but not in the ESC/MEM group, interaction F(1,52) ​= ​4.63, p ​= ​.04. DISCUSSION: In this exploratory analysis, the addition of memantine to escitalopram provided a protective effect on executive functioning in older depressed adults. Future studies are needed to replicate the association of cytokine markers to antidepressant and neuroprotective treatment-related change in cognition in geriatric depression. Elsevier 2020-11-07 /pmc/articles/PMC8474499/ /pubmed/34589902 http://dx.doi.org/10.1016/j.bbih.2020.100167 Text en © 2020 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Full Length Article
Van Dyk, Kathleen
Siddarth, Prabha
Rossetti, Maura
Ercoli, Linda M.
Milillo, Michaela M.
Lavretsky, Helen
Memantine can protect against inflammation-based cognitive decline in geriatric depression
title Memantine can protect against inflammation-based cognitive decline in geriatric depression
title_full Memantine can protect against inflammation-based cognitive decline in geriatric depression
title_fullStr Memantine can protect against inflammation-based cognitive decline in geriatric depression
title_full_unstemmed Memantine can protect against inflammation-based cognitive decline in geriatric depression
title_short Memantine can protect against inflammation-based cognitive decline in geriatric depression
title_sort memantine can protect against inflammation-based cognitive decline in geriatric depression
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474499/
https://www.ncbi.nlm.nih.gov/pubmed/34589902
http://dx.doi.org/10.1016/j.bbih.2020.100167
work_keys_str_mv AT vandykkathleen memantinecanprotectagainstinflammationbasedcognitivedeclineingeriatricdepression
AT siddarthprabha memantinecanprotectagainstinflammationbasedcognitivedeclineingeriatricdepression
AT rossettimaura memantinecanprotectagainstinflammationbasedcognitivedeclineingeriatricdepression
AT ercolilindam memantinecanprotectagainstinflammationbasedcognitivedeclineingeriatricdepression
AT milillomichaelam memantinecanprotectagainstinflammationbasedcognitivedeclineingeriatricdepression
AT lavretskyhelen memantinecanprotectagainstinflammationbasedcognitivedeclineingeriatricdepression